Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update
Clinical Questions Addressed by the CER (5 of 5)
KQ 5 asked: With regard to treatment for preventing osteoporotic fracture:
a. How often should patients be monitored (via measurement of BMD) during therapy, how does bone density monitoring predict antifracture benefits during pharmacotherapy, and does the ability of monitoring to predict antifracture effects of a particular pharmacologic agent vary among the pharmacotherapies?
b. How does the antifracture benefit vary with long-term continued use of pharmacotherapy, and what are the comparative antifracture effects of continued long-term therapy with the various pharmacotherapies?
Keywords: bone | low bone density | bone density | osteoporosis | fracture | osteopenia | skeletal | treatment monitoring | antifracture
- Newberry SJ, Crandall CC, Gellad WG, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update to the 2007 Report. Comparative Effectiveness Review No. 53 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 12-EHC023-EF. Available at www.effectivehealthcare.ahrq.gov/reports/lbd.cfm.
Your slide tray is being processed.